Mr Rainey began his career as staff account manager at Ernst & Young in Philadelphia. From 1997-2008 at Avax, Mr Rainey held several leadership positions including CEO, president, CFO and director.
Mr Rainey has a BS in accounting from Pennsylvania State University and has taken master’s-level courses in taxation from the University of Washington School of Law.
Lee Southard, CEO of VasoGenix, said: “While we are pleased with the data being generated to support our new calcitonin gene related peptide agonist analogs, Rich’s experience in drug development and finance will be a help to the company as we guide VasoGenix into the future.”